Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 16/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7146703 | 0.83 | PDE4B (0.58) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL1194607 | 0.81 | PDE4A (0.62) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL5551736 | 0.81 | PDE4B (0.51) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL7913418 | 0.80 | PDE4A (0.59) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL7359135 | 0.79 | PDE4A (0.55) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL7915754 | 0.79 | PDE4A (0.58) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL7320941 | 0.79 | PDE4B (0.56) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL2913506 | 0.78 | PDE4B (0.50) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL905908 | 0.78 | PDE4B (0.50) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL7084190 | 0.78 | PDE4B (0.50) | PDE4APDE4BPDE4DPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569903-A4 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR THE TREATMENT AND MANAGEMENT OF MYELOPROLIFERATIVE DISEASES | CELGENE CORP (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-1551385-A4 | SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATING MYELODYSPLASTIC SYNDROME | CELGENE CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1496878-A4 | METHODS FOR IDENTIFICATION OF MODULATORS OF ANGIOGENESIS, COMPOUNDS DISCOVERED THEREBY, AND METHODS OF TREATMENT USING THE COMPOUNDS | CELGENE CORP (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1562586-A4 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT, MODIFICATION AND MANAGEMENT OF PAIN | CELGENE CORP (US) | 2007-10-10 | — | — | EP | disclosed |
| EP-1556033-A4 | METHODS AND COMPOSITIONS USING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES | CELGENE CORP (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1569903-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR THE TREATMENT AND MANAGEMENT OF MYELOPROLIFERATIVE DISEASES | CELGENE CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1567148-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT AND MANAGEMENT OF MACULAR DEGENERATION | CELGENE CORPORATION (US) | 2005-08-31 | — | — | EP | disclosed |
| EP-1562586-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT, MODIFICATION AND MANAGEMENT OF PAIN | CELGENE CORPORATION (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1556033-A1 | METHODS AND COMPOSITIONS USING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES | CELGENE CORPORATION (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1551385-A2 | SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATING MYELODYSPLASTIC SYNDROME | Celgene Corporation (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1496878-A1 | METHODS FOR IDENTIFICATION OF MODULATORS OF ANGIOGENESIS, COMPOUNDS DISCOVERED THEREBY, AND METHODS OF TREATMENT USING THE COMPOUNDS | CELGENE CORPORATION (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2004043336-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR THE TREATMENT AND MANAGEMENT OF MYELOPROLIFERATIVE DISEASES | CELGENE CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004041181-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT AND MANAGEMENT OF MACULAR DEGENERATION | CELGENE CORPORATION (US) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004037207-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT, MODIFICATION AND MANAGEMENT OF PAIN | CELGENE CORPORATION (US) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004034962-A2 | SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATING MYELODYSPLASTIC SYNDROME | CELGENE CORPORATION (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2003097040-A1 | METHODS AND COMPOSITIONS USING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES | CELGENE CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003086373-A1 | METHODS FOR IDENTIFICATION OF MODULATORS OF ANGIOGENESIS, COMPOUNDS DISCOVERED THEREBY, AND METHODS OF TREATMENT USING THE COMPOUNDS | CELGENE CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |